JP2022517920A5 - - Google Patents
Info
- Publication number
- JP2022517920A5 JP2022517920A5 JP2021538762A JP2021538762A JP2022517920A5 JP 2022517920 A5 JP2022517920 A5 JP 2022517920A5 JP 2021538762 A JP2021538762 A JP 2021538762A JP 2021538762 A JP2021538762 A JP 2021538762A JP 2022517920 A5 JP2022517920 A5 JP 2022517920A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- antibody
- domain
- protein according
- target fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910023522.6 | 2019-01-10 | ||
| CN201910023522.6A CN111423512B (zh) | 2019-01-10 | 2019-01-10 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| PCT/CN2020/071213 WO2020143720A1 (zh) | 2019-01-10 | 2020-01-09 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022517920A JP2022517920A (ja) | 2022-03-11 |
| JP2022517920A5 true JP2022517920A5 (https=) | 2024-03-12 |
Family
ID=71521813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538762A Ceased JP2022517920A (ja) | 2019-01-10 | 2020-01-09 | 血管内皮細胞の増殖をブロックし、ｔ細胞を活性化する多標的融合タンパク質、およびそれを含有する医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220106389A1 (https=) |
| EP (1) | EP3909986A4 (https=) |
| JP (1) | JP2022517920A (https=) |
| CN (1) | CN111423512B (https=) |
| WO (1) | WO2020143720A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| WO2021185337A1 (zh) * | 2020-03-20 | 2021-09-23 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性融合蛋白及其应用 |
| CN115943165A (zh) * | 2020-05-25 | 2023-04-07 | 北京比洋生物技术有限公司 | Fc-CD80融合蛋白和其缀合物以及它们的用途 |
| MX2023002279A (es) * | 2020-08-27 | 2023-03-10 | Shanghai Junshi Biosciences Co Ltd | Uso de un anticuerpo anti-pd-1 en el tratamiento del carcinoma nasofaringeo. |
| CN115947793B (zh) * | 2021-08-13 | 2023-09-26 | 中国人民解放军总医院 | 靶向pd-l1的超高亲和力小蛋白及用途 |
| US20250188147A1 (en) * | 2022-03-04 | 2025-06-12 | Panalos Bioscience, Inc. | Composition for combi-therapy comprising vegf-grab and pd-1 or pd-l1 antagonist |
| EP4561624A1 (en) * | 2022-07-25 | 2025-06-04 | Agensys, Inc. | Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab |
| WO2024032662A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
| AU2023340044A1 (en) * | 2022-09-14 | 2025-04-03 | Quaerite Biopharm Research (Beijing) Co., Ltd. | Anti-vegfa antibody or antigen-binding fragment thereof and use thereof |
| CN116102624B (zh) * | 2023-03-07 | 2025-10-03 | 南京中医药大学 | 一种具有抑制血管生成作用的线性多肽及其环肽 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298346A3 (en) * | 2002-03-04 | 2011-11-16 | Imclone LLC | Human antibodies specific to kdr and uses thereof |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| TW201006485A (en) * | 2008-06-03 | 2010-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010136480A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| EP2443150B1 (en) * | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP2014506119A (ja) * | 2010-12-02 | 2014-03-13 | ニューロテック ユーエスエー， インコーポレイテッド | 抗血管新生抗体足場および可溶性受容体を分泌する細胞株およびその使用 |
| ES2651521T3 (es) * | 2011-12-01 | 2018-01-26 | Innovent Biologics, Inc. | Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos |
| PE20170255A1 (es) * | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CN104195173B (zh) | 2014-09-02 | 2017-03-08 | 北京比洋生物技术有限公司 | 具有双表达盒的谷氨酰胺合成酶高效表达载体 |
| CA2994631A1 (en) * | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
| US10273281B2 (en) * | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| US10894823B2 (en) * | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| EP4549463A3 (en) * | 2016-06-17 | 2025-07-30 | F. Hoffmann-La Roche AG | Purification of multispecific antibodies |
| SG11201907769XA (en) * | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
| SG11201909160WA (en) * | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
-
2019
- 2019-01-10 CN CN201910023522.6A patent/CN111423512B/zh active Active
-
2020
- 2020-01-09 EP EP20738951.1A patent/EP3909986A4/en not_active Withdrawn
- 2020-01-09 JP JP2021538762A patent/JP2022517920A/ja not_active Ceased
- 2020-01-09 WO PCT/CN2020/071213 patent/WO2020143720A1/zh not_active Ceased
- 2020-01-09 US US17/421,874 patent/US20220106389A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517920A5 (https=) | ||
| JP6124377B2 (ja) | 新規抗ｄｒ５抗体 | |
| JP7196076B2 (ja) | がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子 | |
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| AU2015210420B2 (en) | Anti c-Met antibodies | |
| DK2758073T3 (en) | VEGF / DLL4 BINDING AGENTS AND APPLICATIONS THEREOF | |
| JP2021526816A (ja) | Ｄｌｌ３−ｃｄ３二重特異性抗体 | |
| JP2022515318A5 (https=) | ||
| KR20120024763A (ko) | 항ａｘｌ 항체 | |
| JP2018502050A5 (https=) | ||
| CA2706425A1 (en) | Method for obtaining polypeptide constructs comprising two or more single domain antibodies | |
| JP2013515508A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| CA3208455A1 (en) | Novel anti-gremlin1 antibodies | |
| CA3228641A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2023531672A (ja) | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 | |
| JP2024517953A (ja) | アルファ５ベータ１インテグリン結合剤及びその使用 | |
| CA3119458A1 (en) | Methods and monitoring of treatment with vegf/dll4 binding agent | |
| JP2024508597A5 (https=) | ||
| JPWO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| WO2026067461A1 (en) | Multispecific antibody protein and uses thereof | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| TW202540199A (zh) | 靶向her2及her3之雙特異性四價抗體 | |
| JP2026505164A (ja) | 抗ｃｍｅｔ抗体及びその使用方法 |